
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6096444/publications.pdf Version: 2024-02-01



KEITH LUCON

#	Article	IF	CITATIONS
1	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro-Oncology, 2023, 25, 199-210.	1.2	6
2	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro-Oncology, 2022, 24, 101-113.	1.2	38
3	Multimodal platform for assessing drug distribution and response in clinical trials. Neuro-Oncology, 2022, 24, 64-77.	1.2	4
4	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	1.2	83
5	Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro-Oncology, 2022, 24, 1352-1363.	1.2	29
6	The Alliance AMBUSH Trial: Rationale and Design. Cancers, 2022, 14, 414.	3.7	5
7	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nature Communications, 2022, 13, 604.	12.8	22
8	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. Journal of Neuro-Oncology, 2022, 157, 499-510.	2.9	2
9	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro-Oncology, 2022, 24, 1140-1149.	1.2	13
10	Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas. Neuro-Oncology Advances, 2022, 4, .	0.7	3
11	Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. Journal of Neuro-Oncology, 2022, 158, 111-116.	2.9	5
12	LGG-32. Integrated biologic, radiologic and clinical analysis of pediatric low-grade gliomas during and after targeted therapy treatment. Neuro-Oncology, 2022, 24, i95-i95.	1.2	0
13	OTHR-39. Extraneural spreading of a diffuse leptomeningeal glioneuronal tumor in a child: patient-derived models show sensitivity to vinblastin and trametinib. Neuro-Oncology, 2022, 24, i155-i156.	1.2	0
14	DIPG-54. p53 pathway reactivation as a therapeutic strategy in diffuse intrinsic pontine glioma. Neuro-Oncology, 2022, 24, i31-i31.	1.2	0
15	DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations. Neuro-Oncology, 2022, 24, i28-i28.	1.2	1
16	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. Neuro-Oncology, 2022, 24, i101-i102.	1.2	0
17	DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers. Neuro-Oncology, 2022, 24, i21-i22.	1.2	0
18	LGG-48. The influence of different FGFR1 alterations on pediatric low-grade glioma tumor biology and targeted therapy response. Neuro-Oncology, 2022, 24, i99-i99.	1.2	1

#	Article	IF	CITATIONS
19	LGG-45. Genetic dependencies in <i>MYB/MYBL1</i> -driven pediatric low-grade glioma models. Neuro-Oncology, 2022, 24, i98-i98.	1.2	0
20	Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma. Journal of Neuro-Oncology, 2022, 159, 211-218.	2.9	6
21	Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization Journal of Clinical Oncology, 2022, 40, 2012-2012.	1.6	2
22	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nature Cancer, 2022, 3, 994-1011.	13.2	20
23	Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducinâ€like enhancer 1 in primary intracranial sarcoma, DICER1 â€mutant. Histopathology, 2021, 78, 265-275.	2.9	14
24	Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Modern Pathology, 2021, 34, 264-279.	5.5	16
25	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clinical Cancer Research, 2021, 27, 276-287.	7.0	100
26	Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican. Advanced Therapeutics, 2021, 4, 2000244.	3.2	11
27	DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. Neuro-Oncology Advances, 2021, 3, i12-i13.	0.7	1
28	IDH-mutant gliomas with additional class-defining molecular events. Modern Pathology, 2021, 34, 1236-1244.	5.5	13
29	Inhibitory CD161 receptor identified in glioma-infiltrating TÂcells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	28.9	210
30	Prognostication for meningiomas: H3K27me3 to the rescue?. Neuro-Oncology, 2021, 23, 1218-1219.	1.2	1
31	Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization Journal of Clinical Oncology, 2021, 39, 2014-2014.	1.6	10
32	First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma Journal of Clinical Oncology, 2021, 39, 2009-2009.	1.6	3
33	Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Clioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma Journal of Clinical Oncology, 2021, 39, 2006-2006.	1.6	5
34	LGG-03. LONG-TERM FOLLOW UP OF TARGETED THERAPY IN PEDIATRIC LOW-GRADE GLIOMAS: THE DANA-FARBER/BOSTON CHILDREN'S EXPERIENCE. Neuro-Oncology, 2021, 23, i31-i31.	1.2	0
35	Abstract 1816: Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma. , 2021, , .		0
36	Mutational burden and immune recognition of gliomas. Current Opinion in Oncology, 2021, 33, 626-634.	2.4	5

#	Article	IF	CITATIONS
37	Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1052-1059.	1.7	7
38	Effect of PIK3CA variants on glioma-related epilepsy and response to treatment. Epilepsy Research, 2021, 175, 106681.	1.6	5
39	Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. Cell Reports, 2021, 37, 109788.	6.4	20
40	EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY. Neuro-Oncology, 2021, 23, vi177-vi177.	1.2	0
41	Interim Analysis of Mmrf Curecloud Research Initiative Identifies High Prevalence and Patterns of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations in a Real World Myeloma Cohort. Blood, 2021, 138, 2197-2197.	1.4	0
42	lsomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica, 2020, 139, 193-209.	7.7	83
43	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nature Biotechnology, 2020, 38, 199-209.	17.5	324
44	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene, 2020, 39, 2305-2327.	5.9	31
45	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.7	0
46	Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Reports, 2020, 32, 108196.	6.4	13
47	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell, 2020, 38, 44-59.e9.	16.8	94
48	Epigenomic programming in early fetal brain development. Epigenomics, 2020, 12, 1053-1070.	2.1	9
49	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	28.9	93
50	Socioeconomic Disparities Associated With <i>MGMT</i> Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncology, 2020, 6, 1972.	7.1	22
51	Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. International Journal of Radiation Oncology Biology Physics, 2020, 108, 716-724.	0.8	7
52	MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. American Journal of Neuroradiology, 2020, 41, 874-881.	2.4	15
53	Tumor Interferon Signaling Is Regulated by a IncRNA INCR1 Transcribed from the PD-L1 Locus. Molecular Cell, 2020, 78, 1207-1223.e8.	9.7	43
54	Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nature Genetics, 2020, 52, 219-230.	21.4	37

#	Article	IF	CITATIONS
55	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
56	WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes. JCO Precision Oncology, 2020, 4, 348-354.	3.0	5
57	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii11-ii11.	1.2	1
58	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. Neuro-Oncology, 2020, 22, ii43-ii44.	1.2	3
59	IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii106-ii106.	1.2	1
60	LGG-52. BINIMETINIB IN CHILDREN WITH PROGRESSIVE OR RECURRENT LOW-GRADE GLIOMA NOT ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1: INITIAL RESULTS FROM A MULTI-INSTITUTIONAL PHASE II STUDY. Neuro-Oncology, 2020, 22, iii376-iii376.	1.2	4
61	Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study Journal of Clinical Oncology, 2020, 38, 2568-2568.	1.6	3
62	RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. Neuro-Oncology, 2020, 22, iii443-iii443.	1.2	0
63	LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN <i>MYB</i> AND <i>MYBL1</i> EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii373-iii373.	1.2	0
64	DIPG-22. DISSECTING THE ONCOGENIC ROLE OF <i>FOXR2</i> IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii291-iii291.	1.2	0
65	HGG-52. SUSTAINED RESPONSE TO CRIZOTINIB MONOTHERAPY IN AN INFANT WITH GOPC-ROS1 FUSED CONGENITAL HEMISPHERIC GLIOMA. Neuro-Oncology, 2020, 22, iii353-iii353.	1.2	0
66	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. Neuro-Oncology, 2020, 22, iii311-iii312.	1.2	0
67	DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). Neuro-Oncology, 2020, 22, iii297-iii297.	1.2	0
68	CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB. Neuro-Oncology, 2020, 22, ii53-ii53.	1.2	1
69	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2020, 22, ii44-ii44.	1.2	5
70	EPCO-35. SINGLE-CELL RNA-SEQ OF PEDIATRIC EPENDYMOMA REVEALS PROGNOSTIC IMPACT OF IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION. Neuro-Oncology, 2020, 22, ii76-ii77.	1.2	0
71	BIOM-61. FUNCTIONAL DIAGNOSTIC TESTING OF LIVE-CELL DRUG RESPONSE USING 3D PATIENT DERIVED GLIOBLASTOMA SPHEROIDS ON THE INCUCYTE PLATFORM. Neuro-Oncology, 2020, 22, ii15-ii15.	1.2	0
72	TMOD-34. PATIENT-DERIVED XENOGRAFT AND CELL LINE MODELS FACILITATE NOVEL TREATMENT DISCOVERY IN CENTRAL NERVOUS SYSTEM LYMPHOMAS. Neuro-Oncology, 2020, 22, ii235-ii235.	1.2	0

#	Article	IF	CITATIONS
73	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. Neuro-Oncology, 2020, 22, ii164-ii164.	1.2	0
74	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii228-ii228.	1.2	0
75	RADT-25. EVALUATING LYMPHOCYTE COUNTS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. Neuro-Oncology, 2020, 22, ii186-ii187.	1.2	0
76	A Next Generation Liquid Biopsy Approach for Multiple Myeloma. Blood, 2020, 136, 33-33.	1.4	0
77	TAMI-45. PHENOGENOMIC CHARACTERIZATION OF IMMUNOMODULATORY PURINERGIC SIGNALING IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii222-ii223.	1.2	0
78	EPID-11. A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF THE CLINICAL, GENOMIC, AND SURVIVAL CHARACTERISTICS OF PEDIATRIC, YOUNG ADULT AND OLDER ADULT PATIENTS WITH IDH-MUTANT GLIOMA. Neuro-Oncology, 2020, 22, ii80-ii81.	1.2	1
79	PATH-35. A SCALABLE MOLECULARLY INTEGRATED CLASSIFIER FOR MENINGIOMA OUTPERFORMS WHO CLASSIFICATION. Neuro-Oncology, 2020, 22, ii172-ii172.	1.2	0
80	TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE. Neuro-Oncology, 2020, 22, ii230-ii231.	1.2	1
81	Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nature Communications, 2019, 10, 3731.	12.8	45
82	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Science Translational Medicine, 2019, 11, .	12.4	170
83	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 2019, 178, 835-849.e21.	28.9	1,408
84	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	27.8	273
85	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	1.2	49
86	MEDU-36. BCL2 FAMILY MEMBERS ATTENUATE RESPONSE OF MYC-DRIVEN MEDULLOBLASTOMAS TO BET-BROMODOMAIN INHIBITION. Neuro-Oncology, 2019, 21, ii110-ii111.	1.2	0
87	Phase II trial of ponatinib in patients with bevacizumabâ€refractory glioblastoma. Cancer Medicine, 2019, 8, 5988-5994.	2.8	23
88	Tie2–FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Research, 2019, 79, 5088-5101.	0.9	17
89	Increasing value of autopsies in patients with brain tumors in the molecular era. Journal of Neuro-Oncology, 2019, 145, 349-355.	2.9	6
90	The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nature Communications, 2019, 10, 442.	12.8	86

#	Article	IF	CITATIONS
91	DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs). Neuro-Oncology, 2019, 21, ii70-ii71.	1.2	0
92	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	12.8	37
93	Recurrent <i>EP300-BCOR</i> Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. Journal of Neuropathology and Experimental Neurology, 2019, 78, 305-314.	1.7	29
94	CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma. Scientific Reports, 2019, 9, 4444.	3.3	33
95	Buparlisib in Patients With Recurrent Clioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology, 2019, 37, 741-750.	1.6	103
96	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro-Oncology, 2019, 21, 968-980.	1.2	52
97	Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers, 2019, 11, 2005.	3.7	10
98	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
99	miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene, 2019, 38, 2923-2936.	5.9	45
100	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565, 234-239.	27.8	956
101	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus, 2019, 11, e4726.	0.5	2
102	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	12.6	461
103	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	1.2	64
104	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-Oncology, 2018, 20, 546-556.	1.2	93
105	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. Journal of Neuro-Oncology, 2018, 137, 269-278.	2.9	42
106	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology, 2018, 20, 674-686.	1.2	364
107	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-Oncology, 2018, 20, 1162-1172.	1.2	92
108	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59

#	Article	IF	CITATIONS
109	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 2018, 20, 1547-1555.	1.2	82
110	Intracranial myxoid mesenchymal tumors with <i>EWSR1</i> – <i>CREB</i> family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity?. Brain Pathology, 2018, 28, 183-191.	4.1	72
111	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical Cancer Research, 2018, 24, 295-305.	7.0	68
112	Residual Convolutional Neural Network for the Determination of <i>IDH</i> Status in Low- and High-Grade Gliomas from MR Imaging. Clinical Cancer Research, 2018, 24, 1073-1081.	7.0	297
113	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. JCO Precision Oncology, 2018, 2018, 1-12.	3.0	35
114	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi140-vi141.	1.2	0
115	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. Neuro-Oncology, 2018, 20, vi159-vi159.	1.2	0
116	CMET-45. CHECKPOINT BLOCKADE IMMUNOTHERAPIES FOR MELANOMA BRAIN METASTASES: IMPROVED SURVIVAL OUTCOMES IN A NATIONAL COHORT. Neuro-Oncology, 2018, 20, vi63-vi63.	1.2	0
117	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2018, 20, vi271-vi271.	1.2	0
118	PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi204-vi205.	1.2	3
119	INNV-22. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. Neuro-Oncology, 2018, 20, vi142-vi143.	1.2	0
120	PATH-17. INCREASING VALUE OF AUTOPSIES IN PATIENTS WITH BRAIN TUMORS IN THE MOLECULAR ERA. Neuro-Oncology, 2018, 20, vi161-vi162.	1.2	0
121	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. Neuro-Oncology, 2018, 20, vi13-vi14.	1.2	6
122	PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS. Neuro-Oncology, 2018, 20, vi161-vi161.	1.2	0
123	Microfluidic active loading of single cells enables analysis of complex clinical specimens. Nature Communications, 2018, 9, 4784.	12.8	20
124	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. Neuro-Oncology, 2018, 20, vi8-vi8.	1.2	0
125	Linking single-cell measurements of mass, growth rate, and gene expression. Genome Biology, 2018, 19, 207.	8.8	42
126	TBIO-18. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. Neuro-Oncology, 2018, 20, i184-i184.	1.2	0

#	Article	IF	CITATIONS
127	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell, 2018, 175, 101-116.e25.	28.9	234
128	Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Research, 2018, 78, 4007-4021.	0.9	60
129	The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects. Neuro-Oncology, 2018, 20, 1594-1605.	1.2	21
130	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research, 2018, 6, 1039-1045.	3.4	60
131	Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i> -mutant ganglioglioma. Neurology, 2018, 91, 523-525.	1.1	19
132	PCLN-07. A 3D HYDROGEL CULTURE SYSTEM FACILITATES STUDY OF PRIMARY PEDIATRIC LOW-GRADE GLIOMA CELLS IN VITRO. Neuro-Oncology, 2018, 20, i156-i156.	1.2	0
133	A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nature Communications, 2018, 9, 3116.	12.8	30
134	Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine Journal of Clinical Oncology, 2018, 36, 2020-2020.	1.6	7
135	Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort Journal of Clinical Oncology, 2018, 36, 2011-2011.	1.6	0
136	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma Journal of Clinical Oncology, 2018, 36, 2003-2003.	1.6	1
137	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	1.2	73
138	Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro-Oncology, 2017, 19, now160.	1.2	33
139	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	1.2	99
140	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro-Oncology, 2017, 19, 109-117.	1.2	211
141	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro-Oncology, 2017, 19, now294.	1.2	54
142	A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-Oncology, 2017, 19, now261.	1.2	55
143	G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. Nature Cell Biology, 2017, 19, 177-188.	10.3	107
144	Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology, 2017, 158, 2284-2291.	2.8	53

9

#	Article	IF	CITATIONS
145	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro-Oncology, 2017, 19, 908-917.	1.2	23
146	A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Reports, 2017, 18, 3167-3177.	6.4	32
147	Nuclear inclusion bodies of mutant and wildâ€ŧype p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. Journal of Pathology, 2017, 242, 24-38.	4.5	54
148	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. Journal of Neuro-Oncology, 2017, 135, 581-591.	2.9	15
149	Nuclear CRX and FOXJ1 Expression Differentiates Non–Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. American Journal of Surgical Pathology, 2017, 41, 1410-1421.	3.7	11
150	Brainstem angiocentric gliomas with MYB–QKI rearrangements. Acta Neuropathologica, 2017, 134, 667-669.	7.7	20
151	Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro-Oncology, 2017, 19, 22-30.	1.2	32
152	A novel GIT2-BRAF fusion in pilocytic astrocytoma. Diagnostic Pathology, 2017, 12, 82.	2.0	26
153	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
154	Decreased <scp>FOXJ1</scp> expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. Journal of Pathology, 2016, 238, 584-597.	4.5	29
155	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagnostic Pathology, 2016, 11, 13.	2.0	10
156	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. Journal of Neuro-Oncology, 2016, 128, 293-302.	2.9	51
157	Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nature Neuroscience, 2016, 19, 798-806.	14.8	82
158	Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016, 127, 869-881.	1.4	429
159	Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-Î ² Pathway. Cell Reports, 2016, 16, 950-966.	6.4	49
160	Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nature Biotechnology, 2016, 34, 1161-1167.	17.5	91
161	Genomic characterization of recurrent high-grade astroblastoma. Cancer Genetics, 2016, 209, 321-330.	0.4	17
162	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	12.8	197

#	Article	IF	CITATIONS
163	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine, 2016, 22, 723-726.	30.7	105
164	Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism― New England Journal of Medicine, 2016, 375, 196-198.	27.0	138
165	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurgery, 2016, 85, 96-105.	1.3	14
166	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
167	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	1.2	221
168	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research, 2016, 4, 124-135.	3.4	339
169	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro-Oncology, 2016, 18, 269-274.	1.2	64
170	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type Glioblastomas. Clinical Cancer Research, 2016, 22, 1185-1196.	7.0	89
171	Myxopapillary ependymomas in children: imaging, treatment and outcomes. Journal of Neuro-Oncology, 2016, 126, 165-174.	2.9	39
172	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 2016, 18, 557-564.	1.2	432
173	MAPK activation and <i>HRAS</i> mutation identified in pituitary spindle cell oncocytoma. Oncotarget, 2016, 7, 37054-37063.	1.8	27
174	A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. Journal of Visualized Experiments, 2015, , e53304.	0.3	18
175	Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget, 2015, 6, 1190-1201.	1.8	87
176	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget, 2015, 6, 4704-4716.	1.8	127
177	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro-Oncology, 2015, 17, 1486-1496.	1.2	39
178	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro-Oncology, 2015, 17, 862-867.	1.2	111
179	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	1.6	244
180	Intermediate DNA methylation is a conserved signature of genome regulation. Nature Communications, 2015, 6, 6363.	12.8	91

#	Article	IF	CITATIONS
181	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology, 2015, 17, 1261-1269.	1.2	126
182	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology, 2015, 84, 280-286.	1.1	92
183	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 384-389.	0.8	46
184	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clinical Cancer Research, 2015, 21, 3610-3618.	7.0	79
185	Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology, 2015, 17, 1051-1063.	1.2	178
186	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. Journal of Neuro-Oncology, 2015, 121, 297-302.	2.9	42
187	Calibrating genomic and allelic coverage bias in single-cell sequencing. Nature Communications, 2015, 6, 6822.	12.8	74
188	SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature, 2015, 520, 363-367.	27.8	303
189	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	1.2	40
190	Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology, 2015, 57, 1227-1237.	2.2	79
191	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	9.4	821
192	Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncology, 2015, 1, 662.	7.1	68
193	A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma. Clinical Cancer Research, 2015, 21, 585-593.	7.0	50
194	Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. Neuro-Oncology, 2015, 17, 697-707.	1.2	57
195	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology, 2015, 17, 116-121.	1.2	207
196	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. Neuro-Oncology, 2015, 17, 180-188.	1.2	28
197	One size should not fit all: advancing toward personalized glioblastoma therapy. Discovery Medicine, 2015, 19, 471-7.	0.5	13
198	Prominin-1 (CD133) Defines Both Stem and Non-Stem Cell Populations in CNS Development and Gliomas. PLoS ONE, 2014, 9, e106694.	2.5	30

#	Article	IF	CITATIONS
199	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget, 2014, 5, 10596-10606.	1.8	65
200	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathologica, 2014, 128, 733-741.	7.7	116
201	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	21.4	381
202	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology, 2014, 16, 567-578.	1.2	140
203	BI-20 * GENETIC PROFILING FOR EARLY EVEROLIMUS SENSITIVITY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS ENROLLED ON NCCTG N057K. Neuro-Oncology, 2014, 16, v27-v27.	1.2	0
204	<i>EGFR</i> Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing. Cancer Discovery, 2014, 4, 956-971.	9.4	251
205	Pten Loss in Olig2 Expressing Neural Progenitor Cells and Oligodendrocytes Leads to Interneuron Dysplasia and Leukodystrophy. Stem Cells, 2014, 32, 313-326.	3.2	24
206	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490.	5.9	70
207	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 294-307.	7.4	45
208	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics, 2014, 46, 161-165.	21.4	408
209	Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro-Oncology, 2014, 16, viii1-viii6.	1.2	60
210	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
211	Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11121-11126.	7.1	230
212	ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. Cell Reports, 2014, 6, 313-324.	6.4	106
213	Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study. Epilepsy Research, 2014, 108, 843-852.	1.6	15
214	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. Neuro-Oncology, 2014, 16, v16-v16.	1.2	0
215	SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. Journal of Clinical Investigation, 2014, 124, 1636-1645.	8.2	151
216	Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma Journal of Clinical Oncology, 2014, 32, 2019-2019.	1.6	9

#	Article	IF	CITATIONS
217	A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma Journal of Clinical Oncology, 2014, 32, 2023-2023.	1.6	10
218	Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902) Journal of Clinical Oncology, 2014, 32, 2030-2030.	1.6	2
219	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results Journal of Clinical Oncology, 2014, 32, 2053-2053.	1.6	1
220	Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM) Journal of Clinical Oncology, 2014, 32, 2065-2065.	1.6	1
221	Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy Journal of Clinical Oncology, 2014, 32, 2084-2084.	1.6	3
222	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget, 2014, 5, 8083-8092.	1.8	55
223	Integrative whole-genome copy number analysis and mutation profiling of FFPE brain tumor specimens and potential in designing multi-arm clinical trials Journal of Clinical Oncology, 2014, 32, 11098-11098.	1.6	0
224	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	21.4	674
225	<scp><i>PDGFRA</i></scp> Amplification is Common in Pediatric and Adult Highâ€Grade Astrocytomas and Identifies a Poor Prognostic Group in <scp>IDH</scp> 1 Mutant Glioblastoma. Brain Pathology, 2013, 23, 565-573.	4.1	83
226	Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Research, 2013, 23, 1541-1553.	5.5	138
227	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
228	Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nature Medicine, 2013, 19, 1518-1523.	30.7	127
229	Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1611-1616.	7.1	251
230	Enhancing radiation therapy for patients with glioblastoma. Expert Review of Anticancer Therapy, 2013, 13, 569-581.	2.4	14
231	DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nature Genetics, 2013, 45, 836-841.	21.4	207
232	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nature Genetics, 2013, 45, 285-289.	21.4	532
233	Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. Genome Research, 2013, 23, 1522-1540.	5.5	162
234	Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro-Oncology, 2013, 15, 930-935.	1.2	77

#	Article	IF	CITATIONS
235	Rapid, Label-Free Detection of Brain Tumors with Stimulated Raman Scattering Microscopy. Science Translational Medicine, 2013, 5, 201ra119.	12.4	398
236	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8188-8193.	7.1	188
237	Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM) Journal of Clinical Oncology, 2013, 31, 2015-2015.	1.6	2
238	Combined whole genome copy number genotyping and multiplex somatic mutation profiling of FFPE brain tumor specimens for clinical diagnosis and trial selection Journal of Clinical Oncology, 2013, 31, 2030-2030.	1.6	1
239	Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas Journal of Clinical Oncology, 2013, 31, TPS2104-TPS2104.	1.6	2
240	Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-Oncology, 2012, 14, 819-829.	1.2	117
241	Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro-Oncology, 2012, 14, 1325-1331.	1.2	14
242	Response to Weltman and Fleury Malheiros, re Lassman et al Neuro-Oncology, 2012, 14, 677-678.	1.2	0
243	Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. DMM Disease Models and Mechanisms, 2012, 5, 881-94.	2.4	72
244	Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry. Cancer Research, 2012, 72, 645-654.	0.9	273
245	Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-Oncology, 2012, 14, 761-767.	1.2	48
246	<i>BRAF</i> Duplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper. Journal of Neuropathology and Experimental Neurology, 2012, 71, 789-795.	1.7	59
247	Prospective, high-throughput molecular profiling of human gliomas. Journal of Neuro-Oncology, 2012, 110, 89-98.	2.9	47
248	Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations. Neuron, 2012, 74, 41-48.	8.1	413
249	Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatric Blood and Cancer, 2012, 59, 1155-1157.	1.5	75
250	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 2012, 483, 484-488.	27.8	630
251	DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. PLoS ONE, 2012, 7, e38881.	2.5	28
252	Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development, 2012, 26, 756-784.	5.9	463

#	Article	IF	CITATIONS
253	Somatic Mutations of PIK3R1 Promote Gliomagenesis. PLoS ONE, 2012, 7, e49466.	2.5	49
254	Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget, 2012, 3, 98-106.	1.8	79
255	Genomic characterization of meningiomas Journal of Clinical Oncology, 2012, 30, 2020-2020.	1.6	0
256	Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. Journal of Molecular Diagnostics, 2011, 13, 669-677.	2.8	81
257	BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 2011, 6, e17948.	2.5	268
258	Development of Stereotactic Mass Spectrometry for Brain Tumor Surgery. Neurosurgery, 2011, 68, 280-290.	1.1	58
259	The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma. Cancer Cell, 2011, 19, 359-371.	16.8	141
260	Glioma Models: New GEMMs Add "Class―with Genomic and Expression Correlations. Cancer Cell, 2011, 19, 295-297.	16.8	5
261	Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proceedings of the United States of America, 2011, 108, 20388-20393.	7.1	104
262	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. Journal of Clinical Oncology, 2011, 29, 1424-1430.	1.6	609
263	International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-Oncology, 2011, 13, 649-659.	1.2	138
264	Human Glioma Growth Is Controlled by MicroRNA-10b. Cancer Research, 2011, 71, 3563-3572.	0.9	267
265	Arrayâ€Based Genomics in Glioma Research. Brain Pathology, 2010, 20, 28-38.	4.1	13
266	Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2616-2621.	7.1	63
267	Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. American Journal of Translational Research (discontinued), 2010, 2, 309-15.	0.0	4
268	CRX Is a Diagnostic Marker of Retinal and Pineal Lineage Tumors. PLoS ONE, 2009, 4, e7932.	2.5	43
269	Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults. Clinical Cancer Research, 2009, 15, 330-337.	7.0	147
270	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. Clinical Cancer Research, 2009, 15, 6430-6437.	7.0	88

#	Article	IF	CITATIONS
271	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor) Tj ETQq1 1 0.78431	4 rgBT /O\ 1.2	verlock 10
272	Myelin Gene Regulatory Factor Is a Critical Transcriptional Regulator Required for CNS Myelination. Cell, 2009, 138, 172-185.	28.9	427
273	FoxOs Cooperatively Regulate Diverse Pathways Governing Neural Stem Cell Homeostasis. Cell Stem Cell, 2009, 5, 540-553.	11.1	418
274	Meningioangiomatosis Associated with Meningioma. Acta Cytologica, 2009, 53, 93-97.	1.3	14
275	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS ONE, 2009, 4, e7887.	2.5	316
276	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 2008, 455, 1129-1133.	27.8	658
277	RESEARCH ARTICLE: Myelin Abnormalities without Oligodendrocyte Loss in Periventricular Leukomalacia. Brain Pathology, 2008, 18, 153-163.	4.1	221
278	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. Cancer Cell, 2008, 13, 355-364.	16.8	109
279	Acquisition of Granule Neuron Precursor Identity Is a Critical Determinant of Progenitor Cell Competence to Form Shh-Induced Medulloblastoma. Cancer Cell, 2008, 14, 123-134.	16.8	572
280	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology, 2008, 10, 300-308.	1.2	88
281	A Novel <i>TP53</i> Germline Mutation in a Family with a History of Multiple Malignancies: Case Report and Review of the Literature. Pediatric Neurosurgery, 2008, 44, 501-508.	0.7	3
282	Expression of p16Ink4a Compensates for p18Ink4c Loss in Cyclin-Dependent Kinase 4/6–Dependent Tumors and Tissues. Cancer Research, 2007, 67, 4732-4741.	0.9	58
283	Embryonic Stem Cell Transcription Factor Signatures in the Diagnosis of Primary and Metastatic Germ Cell Tumors. American Journal of Surgical Pathology, 2007, 31, 836-845.	3.7	169
284	Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma. Neuron, 2007, 53, 503-517.	8.1	438
285	Disruption of Diacylglycerol Kinase Delta (DGKD) Associated with Seizures in Humans and Mice. American Journal of Human Genetics, 2007, 80, 792-799.	6.2	39
286	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science, 2007, 318, 287-290.	12.6	849
287	Semiautomated Multiplexed Quantum Dot-Based in Situ Hybridization and Spectral Deconvolution. Journal of Molecular Diagnostics, 2007, 9, 20-29.	2.8	42
288	Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Annals of Neurology, 2007, 62, 515-520.	5.3	261

#	Article	IF	CITATIONS
289	Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Development, 2007, 21, 2683-2710.	5.9	1,952
290	Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. Developmental Biology, 2006, 292, 152-164.	2.0	19
291	Expression of Oligodendroglial and Astrocytic Lineage Markers in Diffuse Gliomas. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1149-1156.	1.7	64
292	Comparative Analysis of Germ Cell Transcription Factors in CNS Germinoma Reveals Diagnostic Utility of NANOG. American Journal of Surgical Pathology, 2006, 30, 1613-1618.	3.7	49
293	p16INK4a induces an age-dependent decline in islet regenerative potential. Nature, 2006, 443, 453-457.	27.8	922
294	<i>Olig</i> gene function in CNS development and disease. Glia, 2006, 54, 1-10.	4.9	197
295	Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities. Cancer Research, 2006, 66, 11502-11513.	0.9	187
296	A Novel Somatic Mouse Model to Survey Tumorigenic Potential Applied to the Hedgehog Pathway. Cancer Research, 2006, 66, 10171-10178.	0.9	257
297	Development of NG2 neural progenitor cells requires Olig gene function. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7853-7858.	7.1	178
298	Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2005, 64, 948-955.	1.7	85
299	Diffusion-weighted imaging of fungal cerebral infection. American Journal of Neuroradiology, 2005, 26, 1115-21.	2.4	90
300	Molecular diversity of astrocytes with implications for neurological disorders. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8384-8389.	7.1	193
301	The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas. Journal of Neuropathology and Experimental Neurology, 2004, 63, 499-509.	1.7	384
302	Arginase deficiency with lethal neonatal expression: Evidence for the glutamine hypothesis of cerebral edema. Journal of Pediatrics, 2003, 142, 349-352.	1.8	44
303	Epidermal growth factor receptor and Ink4a/Arf. Cancer Cell, 2002, 1, 269-277.	16.8	618
304	Cooperative Transcriptional Activation by the Neurogenic Basic Helix-Loop-Helix Protein MASH1 and Members of the Myocyte Enhancer Factor-2 (MEF2) Family. Journal of Biological Chemistry, 1996, 271, 26659-26663.	3.4	69
305	Paraxis: A Basic Helix-Loop-Helix Protein Expressed in Paraxial Mesoderm and Developing Somites. Developmental Biology, 1995, 168, 296-306.	2.0	198
306	Detection ofp53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. Journal of Neuro-Oncology, 1993, 16, 125-133.	2.9	10